Advances in multiple myeloma therapy are suppressing the dreaded expectations of a daunting disease. How are the latest treatment modalities presenting new avenues for cancer therapy? How can we work to improve our awareness of the changing face of multiple myeloma? Dr. James Berenson, founding president and chief executive officer of the Institute for Myeloma and Bone Cancer Research in West Hollywood, Calif., explores developments in multiple myeloma therapy that are improving prognoses for our patients. Dr. Mark Nolan Hill hosts.
Improving the Prognoses of Multiple Myeloma
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Advances in multiple myeloma therapy are suppressing the dreaded expectations of a daunting disease. How are the latest treatment modalities presenting new avenues for cancer therapy? How can we work to improve our awareness of the changing face of multiple myeloma? Dr. James Berenson, founding president and chief executive officer of the Institute for Myeloma and Bone Cancer Research in West Hollywood, Calif., explores developments in multiple myeloma therapy that are improving prognoses for our patients. Dr. Mark Nolan Hill hosts.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
MinuteCE®
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
1.00 credits
<p>Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Cardiology
FINE-HEART Pooled Analysis
<p><span data-teams="true">FINE-HEART Pooled Analysis</span></p>
Cardiology
NYHA FC and Finerenone Response: Clinical Trial Insights
<p><span data-contrast="auto" xml:lang="EN-US">NYHA FC and Finerenone Response: Clinical Trial Insights</span><span data-ccp-props='{"134245417":false,"335559739":0}'> </span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?